Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, gram-negative bacilli and respiratory tract pathogens.
The in vitro activity of cefdinir (CI-983; FK-482), a new oral cephalosporin, was compared with that of other antimicrobial agents against clinical isolates of staphylococci, gram-negative bacilli and common respiratory tract pathogens. Cefdinir (MIC90 less than or equal to 2.0 micrograms/ml) was more active than cefixime (MIC90 greater than 64 micrograms/ml) and equally as active as cefuroxime (MIC90 2.0 micrograms/ml) against oxacillin-susceptible staphylococci. Cefdinir was active against Haemophilus influenzae, including beta-lactamase producers (MIC90 0.5 microgram/ml), Moraxella catarrhalis (MIC90 less than or equal to 0.12 microgram/ml), Streptococcus pneumoniae (MIC90 less than or equal to 0.06 microgram/ml) and Streptococcus pyogenes (MIC90 less than or equal to 0.06 microgram/ml). The activity of cefdinir against gram-negative bacilli was variable; organisms with chromosomal cephalosporinases were often resistant.
Scriver
S R
SR
Department of Microbiology, Mount Sinai Hospital, University of Toronto, Ontario, Canada.
Willey
B M
BM
Low
D E
DE
Simor
A E
AE
D001419:Bacteria / Q000187:drug effects*; D000077525:Cefdinir; D002511:Cephalosporins / Q000494:pharmacology*; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D012137:Respiratory System / Q000382:microbiology*; D013210:Staphylococcus / Q000187:drug effects*
D002511:Cephalosporins; D000077525:Cefdinir